- Chemoresistant myeloid sarcoma responding to salvage therapy with combined azacitidine and venetoclax2022 | First Faculty of Medicine
- Venetoclax - new drones to deploy against chronic lymphocytic leukemia2018 | Third Faculty of Medicine
- Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma2019 | First Faculty of Medicine, Second Faculty of Medicine
- Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen2022 | Faculty of Medicine in Hradec Králové
- Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia2022 | Third Faculty of Medicine
- Fixed duration therapy in patients with chronic lymphocytic leukemia2023 | Publication without faculty affiliation
- Time-limited therapy with the combination of venetoclax and obinutuzumab in the first-line treatment of chronic lymphocytic leukemia2023 | Publication without faculty affiliation
- Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial2023 | Faculty of Medicine in Hradec Králové
- Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities2022 | Publication without faculty affiliation
- A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma2021 | First Faculty of Medicine
- Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial2020 | Third Faculty of Medicine
- Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study2023 | Publication without faculty affiliation
- Treatment of relapsed chronic lymphocytic leukemia2019 | First Faculty of Medicine
- Skipping a step or "impatientitis": what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?2021 | Faculty of Medicine in Hradec Králové
- Biologická léčba u systémových amyloidóz2023 | First Faculty of Medicine
- Treatment of repeatedly relapsing chronic lymphocytic leukemia2018 | Faculty of Medicine in Hradec Králové
- BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas2020 | First Faculty of Medicine
- BH3 Mimetics in Hematologic Malignancies2021 | First Faculty of Medicine, Central Library of Charles University
- Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas2022 | First Faculty of Medicine
- Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?2021 | Faculty of Medicine in Hradec Králové
- Richter transformation of chronic lymphocytic leukaemia in the era of treatment with B-cell signalling pathway inhibitors2020 | First Faculty of Medicine
- Modern approach to the treatment of chronic lymphocytic leukemia2023 | Faculty of Medicine in Hradec Králové
- Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation2017 | Publication without faculty affiliation
- 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy2021 | Third Faculty of Medicine
- Use of ibrutinib as "bridging" for allogeneic hematopoietic stem cell transplantation from haploidentic donor and subsequent therapy of residual disease after transplantation in a patient with highly adverse mantle cell lymphoma2019 | First Faculty of Medicine
- Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy2022 | Third Faculty of Medicine
- Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle2020 | Faculty of Medicine in Hradec Králové
- Recommendations for chronic lymphocytic leukaemia diagnosis and therapy 20212021 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- Treatment of elderly and comorbid patients with chronic lymphocytic leukemia2017 | Faculty of Medicine in Hradec Králové
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine